===
EQS-News: Gerresheimer AG / Key word(s): Contract/Investment
Gerresheimer partners with RxCap to offer connected adherence solutions
2024-04-29 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Gerresheimer partners with RxCap to offer connected adherence solutions
. Gerresheimer subsidiary Centor receives exclusive distribution rights for pharmacies in the U.S.
. Adherence solutions enables pharmacies to offer remote therapeutic monitoring
. Digital therapy support leads to improved health outcomes
Düsseldorf/Berlin, Ohio, USA, April 29, 2024 - Gerresheimer, an innovative systems and solutions provider and global
partner for the pharma, biotech and cosmetics industries, has entered into a partnership with the US digital health
company RxCap and acquired a minority stake. Under the terms of the agreement, Gerresheimer's subsidiary Centor will
receive the exclusive distribution rights for pharmacies in the U.S. for adherence solutions by RxCap, consisting of
connected prescription vial closure devices and complementary cloud-based software. Centor is the U.S. market leader in
prescription vials and is uniquely positioned to enable smart adherence solutions through existing pharmacy workflows.
"The adherence solutions from RxCap is an ideal complement to the Centor prescription vials", says Tony Haba, Senior
Vice President North America at Gerresheimer. "Solutions for digital therapy support are a future growth market for
Gerresheimer. That is why we are increasingly offering our customers innovative solutions consisting of connected
primary packaging and digital monitoring platforms. The partnership with RxCap is an excellent example of this."
"Our mission is to help people stay adherent to their medications and improve their care outcomes," says Sreeram
Ramakrishnan, CEO of RxCap. "By partnering with Centor - an innovative market leader with strong relations with
pharmacies, we will be able to grow the number of patients we serve. Moreover, Gerresheimer's expertise in primary
packaging and access to pharmacy leaders will enable us to develop additional adherence solutions that amplify our
impact."
Minority shareholding and seat on the Board of Directors
As part of the partnership, Gerresheimer has acquired a minority stake in RxCap in addition to the exclusive
distribution rights for pharmacies in the United States. Gerresheimer will also appoint a representative to RxCap's
Board of Directors.
Remote Therapeutic Monitoring
Patient adherence to medication is crucial for therapy outcome and can prevent cost-intensive hospitalizations. Digital
therapy support is becoming increasingly important in this area, not only through body-worn sensors and apps, but also
through connected primary packaging and delivery systems and medication adherence monitoring.
Under the partnership agreement Centor will offer RxCap's suite of connected prescription vial closure devices and
complementary cloud-based software to pharmacies to help them monitor their patients' prescription adherence. These
solutions require no additional effort from the patient and can easily be integrated with existing enterprise workflows
to manage patient needs effectively.
Using a cellular signal, the RxCap reports to the cloud-based software platform when the prescription vial has been
opened. Pharmacy staff can easily and quickly assess whether the medication has been taken as prescribed and remind the
patient to take the medication by text message or phone call.
This partnership will enable pharmacies to quickly launch adherence solutions that can support patient's health journey
more effectively, with minimal additional investments in their workflow, and create new revenue streams.
RxCap now available for U.S. pharmacies
The RxCap solution is now available for U.S. pharmacies and can be ordered directly from Centor. Centor is thus
expanding its product offering in the U.S., positioning itself in the market for remote therapeutic monitoring and also
benefiting from recurring revenues while making significant impact on patient health outcomes.
For order inquiries and questions, pharmacies can contact Centor at prescription@centorrx.com.

About RxCap
RxCap, Inc. is a Boston-based prescription adherence technology corporation enabling better patient outcomes and
reducing health care costs. The company supports healthcare enterprises in developing customized remote therapeutic
monitoring programs with a modular suite of enablement software, APIs, and prescription adherence devices. By
partnering with RxCap, enterprises can quickly build revenue-generating RPM programs that integrate with their existing
care workflows.
www.rxcap.com

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech, and cosmetic
industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems
and medical devices as well as solutions for the health industry. The product range includes digital solutions for
therapy support, medication pumps, syringes, pens, auto-injectors, and inhalers as well as vials, ampoules, tablet
containers, dropper bottles, other bottles and more. Gerresheimer ensures the safe delivery and reliable administration
of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a
global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues
of around EUR2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com
Contact Gerresheimer AG
Media

Jutta Lorberg                     Marion Stolzenwald 
Head of Corporate Communication   Senior Manager Corporate Communication 
T +49 211 6181 264                T +49 172 2424185 
jutta.lorberg@gerresheimer.com    marion.stolzenwald@gerresheimer.com 

Investor Relations
Guido Pickert Thomas Rosenke
Vice President Investor Relations Senior Manager Investor Relations

T +49 152 900 14145               T: +49 211 6181-187 
gerresheimer.ir@gerresheimer.com  gerresheimer.ir@gerresheimer.com 

===
-----------------------------------------------------------------------------------------------------------------------

2024-04-29 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

-----------------------------------------------------------------------------------------------------------------------

===

Language:     English 
Company:      Gerresheimer AG 

Klaus-Bungert-Str. 4
40468 Duesseldorf
Germany

Phone:        +49-(0)211/61 81-00 
Fax:          +49-(0)211/61 81-121 
E-mail:       gerresheimer.ir@gerresheimer.com 
Internet:     http://www.gerresheimer.com 
ISIN:         DE000A0LD6E6 
WKN:          A0LD6E 
Indices:      MDAX (Aktie) 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1891675

End of News EQS News Service
===
1891675 2024-04-29 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1891675&application_name=news

END) Dow Jones Newswires

April 29, 2024 07:00 ET (11:00 GMT)